ICON Public FY2025 EPS Estimate Decreased by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR) – Equities research analysts at Leerink Partnrs dropped their FY2025 earnings estimates for ICON Public in a report issued on Monday, March 3rd. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will earn $13.29 per share for the year, down from their prior estimate of $13.65. The consensus estimate for ICON Public’s current full-year earnings is $13.38 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.68 EPS and FY2027 earnings at $17.83 EPS.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The company had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion.

Other equities research analysts have also issued reports about the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. William Blair restated an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. JPMorgan Chase & Co. dropped their price target on ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Citigroup reduced their price objective on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Finally, Truist Financial cut their target price on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $279.17.

ICON Public Stock Down 0.6 %

NASDAQ ICLR opened at $183.62 on Wednesday. ICON Public has a 52 week low of $179.50 and a 52 week high of $347.72. The company has a quick ratio of 1.34, a current ratio of 1.26 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $14.83 billion, a P/E ratio of 19.27, a price-to-earnings-growth ratio of 1.86 and a beta of 1.19. The stock’s 50-day moving average price is $200.78 and its 200-day moving average price is $238.28.

Hedge Funds Weigh In On ICON Public

Several hedge funds have recently bought and sold shares of the business. Foyston Gordon & Payne Inc boosted its stake in shares of ICON Public by 27.3% during the fourth quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock valued at $10,845,000 after purchasing an additional 11,089 shares during the period. Captrust Financial Advisors boosted its position in ICON Public by 2.0% in the 4th quarter. Captrust Financial Advisors now owns 35,301 shares of the medical research company’s stock valued at $7,403,000 after buying an additional 701 shares during the period. State of Tennessee Department of Treasury grew its stake in ICON Public by 1.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock worth $33,333,000 after acquiring an additional 1,600 shares in the last quarter. Motley Fool Wealth Management LLC boosted its holdings in shares of ICON Public by 2.3% in the fourth quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after purchasing an additional 1,466 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in ICON Public by 128.2% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company’s stock worth $245,000 after purchasing an additional 655 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.